Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 5/20 | 0.44 |
| ▸ | CDK2 | P24941 | 5/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230251 | 0.91 | CDK2 (0.44) | CCNA2CDK2CCNA1YTHDC1IKBKB | |
| SCHEMBL5228506 | 0.89 | CCNA2 (0.46) | CCNA2CDK2CCNA1YTHDC1CCR1 | |
| SCHEMBL5226367 | 0.87 | CCNA2 (0.55) | CCNA2CDK2CCNA1LRRK2PIK3CA | |
| SCHEMBL12886440 | 0.84 | CDK2 (0.46) | CCNA2CDK2CCNA1YTHDC1 | |
| SCHEMBL5225572 | 0.84 | CCNA2 (0.52) | CCNA2CDK2CCNA1GAA | |
| SCHEMBL5226285 | 0.81 | CCNA2 (0.58) | CCNA2CDK2CCNA1CCR1GAA | |
| SCHEMBL5227507 | 0.77 | CDK2 (0.54) | CCNA2CDK2CCNA1BRAFIKBKB | |
| SCHEMBL5225835 | 0.76 | CCNA2 (0.57) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL5225870 | 0.75 | CDK2 (0.56) | CCNA2CDK2CCNA1 | |
| SCHEMBL5229147 | 0.74 | CCNA2 (0.56) | CCNA2CDK2CCNA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | claimed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | claimed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | disclosed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | TP53, NFATC1, MAP3K15 | CCNA2 1338/4885CDK2 178/4885CCNA1 1187/4885 |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | CCNA2 1285/4885CDK2 171/4885CCNA1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.